These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2675003)

  • 21. [Cytokine therapy of superficial bladder carcinoma. Mechanisms of action and results of therapy].
    Otto T; Kälble T
    Urologe A; 1994 Nov; 33(6):540-6. PubMed ID: 7817454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravesical therapy for superficial bladder cancer.
    Malkowicz SB
    Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapy of superficial bladder cancer.
    Nseyo UO; Lamm DL
    Semin Oncol; 1996 Oct; 23(5):598-604. PubMed ID: 8893870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Severe self-limiting hypersensitivity reaction after immunotherapy with intravesical BCG].
    Estelles Piera FJ; Campayo A; Valls Ferrer JM; Lacruz J; Blanes Julia FM; López Aldeguer J; Bonora Tamarit V
    An Med Interna; 1994 Oct; 11(10):503-5. PubMed ID: 7865660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG.
    Sanchez-Carbayo M; Urrutia M; Romani R; Herrero M; Gonzalez de Buitrago JM; Navajo JA
    Anticancer Res; 2001; 21(4B):3041-7. PubMed ID: 11712808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment and follow-up of superficial bladder cancer].
    Raitanen M
    Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
    [No Abstract]   [Full Text] [Related]  

  • 27. In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guérin therapy without previous transurethral resection of the prostate.
    Palou J; Xavier B; Laguna P; Montlleó M; Vicente J
    Urology; 1996 Apr; 47(4):482-4. PubMed ID: 8638354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The immunotherapy and immunoprophylaxis of bladder cancer].
    Figurin KM; Tsiganu VI
    Urol Nefrol (Mosk); 1993; (4):46-9. PubMed ID: 8310570
    [No Abstract]   [Full Text] [Related]  

  • 29. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
    Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ
    Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662
    [No Abstract]   [Full Text] [Related]  

  • 30. Editorial: urothelial tumors--liberal applications of conservative approaches.
    Droller MJ
    J Urol; 2003 Mar; 169(3):936-7. PubMed ID: 12576816
    [No Abstract]   [Full Text] [Related]  

  • 31. New-onset psoriasis and psoriatic arthritis in a patient treated with Bacillus Calmette-Guérin (BCG) immunotherapy.
    Dudelzak J; Curtis AR; Sheehan DJ; Lesher JL
    J Drugs Dermatol; 2008 Jul; 7(7):684. PubMed ID: 18664162
    [No Abstract]   [Full Text] [Related]  

  • 32. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors.
    Palou J; Laguna P; Millán-Rodríguez F; Hall RR; Salvador-Bayarri J; Vicente-Rodríguez J
    J Urol; 2001 May; 165(5):1488-91. PubMed ID: 11342902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results.
    Pansadoro V; Emiliozzi P; Defidio L; Donadio D; Florio A; Maurelli S; Lauretti S; Sternberg CN
    J Urol; 1995 Dec; 154(6):2054-8. PubMed ID: 7500457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunotherapy in superficial bladder carcinoma].
    Ríos González E; Martínez-Piñeiro Lorenzo L; Martínez-Piñeiro Caramés JA; de la Peña Barthel JJ
    Arch Esp Urol; 2000 Dec; 53(10):879-92. PubMed ID: 11213392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
    Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contemporary management of stage T1 transitional cell carcinoma of the bladder.
    Sataa S; Yassine N; Ghassen HH; Imed BS; Mohamed C; Maher C; Ali H
    Tunis Med; 2005 Dec; 83 Suppl 12():87-9. PubMed ID: 16430077
    [No Abstract]   [Full Text] [Related]  

  • 37. The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ.
    Brosman S
    Prog Clin Biol Res; 1989; 310():193-205. PubMed ID: 2771993
    [No Abstract]   [Full Text] [Related]  

  • 38. Neopterin as a monitoring parameter for treatment with BCG in superficial bladder cancer.
    Mack D; Gomahr A; Herold M; Frick J
    Eur J Cancer; 1995 Jun; 31A(6):1025-6. PubMed ID: 7646907
    [No Abstract]   [Full Text] [Related]  

  • 39. [Effect of immunotherapy on bladder cancer].
    Watanabe K; Suzuki T; Takahashi N; Kawaguchi T; Kudo T; Kogawa T; Funyu T
    Nihon Hinyokika Gakkai Zasshi; 1987 Jun; 78(6):1092-102. PubMed ID: 3682501
    [No Abstract]   [Full Text] [Related]  

  • 40. Aspects of non-specific immunotherapy with BCG in superficial bladder cancer: an overview.
    van der Meijden AP; Debruyne FM; Steerenberg PA; de Jong WH
    Prog Clin Biol Res; 1989; 310():11-33. PubMed ID: 2672011
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.